5.25
price up icon38.49%   1.4591
after-market Dopo l'orario di chiusura: 5.16 -0.09 -1.71%
loading

Bioline Rx Ltd Adr Borsa (BLRX) Ultime notizie

pulisher
03:03 AM

BioLineRx ADR: Positive Earnings Call Highlights and Challenges - MSN

03:03 AM
pulisher
May 31, 2025

BioLineRx upgraded to Buy from Hold at JonesResearch - Yahoo Finance

May 31, 2025
pulisher
May 30, 2025

BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating By Stocktwits - Investing.com India

May 30, 2025
pulisher
May 30, 2025

BioLineRx announces new data from Phase 2 combination trial of motixafortide - TipRanks

May 30, 2025
pulisher
May 30, 2025

Jones Trading raises BioLineRx stock rating, targets $12 By Investing.com - Investing.com South Africa

May 30, 2025
pulisher
May 30, 2025

Jones Trading raises BioLineRx stock rating, targets $12 - Investing.com India

May 30, 2025
pulisher
May 30, 2025

BioLineRx Presents Promising Phase 2 Data at ASCO 2025 for Pancreatic Cancer Trial - TipRanks

May 30, 2025
pulisher
May 30, 2025

BioLineRx reports promising pancreatic cancer trial data By Investing.com - Investing.com India

May 30, 2025
pulisher
May 30, 2025

BioLineRx reports promising pancreatic cancer trial data - Investing.com

May 30, 2025
pulisher
May 28, 2025

Jones Trading maintains Hold on BioLineRx stock amid royalty prospects By Investing.com - Investing.com India

May 28, 2025
pulisher
May 28, 2025

H.C. Wainwright Maintains Buy Rating, $26 Target on BioLineRx Stock - Investing.com

May 28, 2025
pulisher
May 28, 2025

BioLineRx: Strong Financials and Promising Clinical Developments Drive Buy Rating - TipRanks

May 28, 2025
pulisher
May 27, 2025

BioLineRx Ltd. Reports Q1 2025 Financial Results - TipRanks

May 27, 2025
pulisher
May 27, 2025

BioLineRx Q1 Earnings Rise Despite Fall In Revenue: Retail Stays Super Confident By Stocktwits - Investing.com India

May 27, 2025
pulisher
May 27, 2025

BioLineRx Reports Q1 2025 Financial Results and Strategic Updates - TipRanks

May 27, 2025
pulisher
May 27, 2025

Options Volatility and Implied Earnings Moves Today, May 27, 2025 - TipRanks

May 27, 2025
pulisher
May 23, 2025

BioLineRx Ltd. Schedules Annual Shareholder Meeting for June 2025 - TipRanks

May 23, 2025
pulisher
May 09, 2025

Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and CVRx (CVRX) - The Globe and Mail

May 09, 2025
pulisher
Apr 01, 2025

BioLineRx stock rating cut to Hold at Jones Trading - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

BLRX stock touches 52-week low at $2.85 amid sharp annual decline - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

H.C. Wainwright raises BioLineRx stock target to $26 - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

BioLineRx Ltd. Reports 2024 Financial Results and Strategic Progress - TipRanks

Apr 01, 2025
pulisher
Mar 31, 2025

BioLineRx Earnings Call: Strategic Shifts and Growth - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

BioLineRx price target adjusted to $26 at H.C. Wainwright after reverse split - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Options Volatility and Implied Earnings Moves This Week, March 31 – April 03, 2025 - The Globe and Mail

Mar 31, 2025
pulisher
Mar 31, 2025

BioLineRx Reports Strong 2024 Financial Results and Strategic Advancements - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Options Volatility and Implied Earnings Moves Today, March 31, 2025 - TipRanks

Mar 31, 2025
pulisher
Mar 07, 2025

Bioline RX Ltd Sponsored ADR to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Feb 27, 2025

Investor Network: Bioline RX Ltd Sponsored ADR to Host Earnings Call - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 19, 2025

BLRX: Aphexda Transition Progressing - Research Tree

Feb 19, 2025
pulisher
Jan 31, 2025

BioLineRx stock hits 52-week low at $3.24 amid sharp decline - Investing.com India

Jan 31, 2025
pulisher
Jan 21, 2025

BioLineRx announces strategic shift with licensing deals - Investing.com

Jan 21, 2025
pulisher
Jan 21, 2025

BioLineRx Outlines Strategic Vision and Financial Outlook After Key Licensing Deals - TipRanks

Jan 21, 2025
pulisher
Jan 17, 2025

BioLineRx Adjusts ADS Ratio to Maintain Nasdaq Listing - TipRanks

Jan 17, 2025
pulisher
Jan 17, 2025

BioLineRx Announces 1:40 ADS Ratio Change, Confirms $29.5M Cash Runway Through 2026 - Stock Titan

Jan 17, 2025
pulisher
Jan 13, 2025

BioLineRx stock touches 52-week low at $0.14 amid downturn - Investing.com India

Jan 13, 2025
pulisher
Jan 13, 2025

BioLineRx stock touches 52-week low at $0.14 amid downturn By Investing.com - Investing.com South Africa

Jan 13, 2025
pulisher
Jan 07, 2025

BiolineRx Announces Major Direct Offering to Bolster Operations - TipRanks

Jan 07, 2025
pulisher
Jan 06, 2025

BioLineRx stock plunges to 52-week low of $0.19 amid market challenges - Investing.com

Jan 06, 2025
pulisher
Jan 06, 2025

BioLineRx Announces $10 Million Direct Offering to Fuel Growth - TipRanks

Jan 06, 2025
pulisher
Jan 06, 2025

BioLineRx Raises $10M in Direct Offering at $0.20 Per ADS with Matching Warrants - Stock Titan

Jan 06, 2025
pulisher
Dec 16, 2024

BioLineRx stock hits 52-week low at $0.21 amid market challenges - Investing.com

Dec 16, 2024
pulisher
Dec 06, 2024

BioLineRx stock plunges to 52-week low, hits $0.25 - Investing.com India

Dec 06, 2024
pulisher
Nov 26, 2024

BioLineRx stock target cut, retains buy on Q3 financial results - Investing.com

Nov 26, 2024
pulisher
Nov 25, 2024

BioLineRx Reports Strategic Moves in Q3 2024 - TipRanks

Nov 25, 2024
pulisher
Nov 25, 2024

BioLineRx earnings beat by $0.04, revenue topped estimates By Investing.com - Investing.com South Africa

Nov 25, 2024
pulisher
Nov 25, 2024

Earnings call: BioLineRx announces Q3 results and strategic shifts - Investing.com

Nov 25, 2024
pulisher
Nov 25, 2024

Earnings call: BioLineRx announces Q3 results and strategic shifts By Investing.com - Investing.com South Africa

Nov 25, 2024
pulisher
Nov 25, 2024

BioLineRx Secures Key Deals to Boost Shareholder Value - TipRanks

Nov 25, 2024
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Capitalizzazione:     |  Volume (24 ore):